Navigation Links
Nektar Consolidates Research at Its State-of-the-Art R&D Center Located in San Francisco at Mission Bay
Date:3/20/2012

rs: (i) Nektar's drug candidates and those of our collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the commercial launch of our drug candidates may be delayed or unsuccessful due to regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (iii) scientific discovery of new medical breakthroughs is an inherently uncertain process and the future success of the application of our technology platform to potential new drug candidates is therefore highly uncertain and unpredictable and one or more research and development programs could fail; and (iv) certain other important risks and uncertainties set forth in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 29, 2012. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Nektar Investor Inquiries:
Jennifer Ruddock/Nektar Therapeutics                                 (415) 482-5585
Susan Noonan/SA Noonan Communications,
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Research and Development Trend Forecast of Pharmaceutical ... offering. Research and Development Trend Forecast ... , 2014-2018 mainly analyzes China,s ... status, supply & demand, competition landscape, and business performance ...
(Date:8/29/2014)... DALLAS , August 29, 2014 ... Synthesis Market by Product & Services (Equipment, Reagent, ... Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, ... by MarketsandMarkets, the global Oligonucleotide Synthesis Market is ... $1,070.7 Million in 2014, growing at a CAGR ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... FORT LAUDERDALE, Fla., Aug. 20 OmniComm Systems, Inc. ... in the EDC marketplace, today announced that Impax Pharmaceuticals, the ... the TrialMaster EDC solution for conducting a Phase III study ... site clinical trial there can be significant challenges in getting ...
... , MOFFETT FIELD, Calif., Aug. 19 ... for the ancient fusing of two microscopic, single-celled organisms called ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081007/38461LOGO ) , , By ... a type of single-celled organism without a nucleus -- molecular ...
Cached Medicine Technology:Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease 2Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinson's Disease 3NASA Research Reveals Major Insight Into Evolution of Life on Earth 2
(Date:8/31/2014)... (PRWEB) August 31, 2014 For many, fall ... likely the culprit. Ragweed is the most common cause of ... Americans. , The most common symptoms of ragweed allergy include ... and sneezing. Ragweed allergy can also lead to wheezing, asthma ... should consult an allergist about allergy immunotherapy - the only ...
(Date:8/31/2014)... With years of hard work, Delta has now become one ... the company has updated its wheel loader assortment ... these items are guaranteed to be great. Additionally, they are ... is true that all items in Delta’s used cat ... The firm is making full efforts to help worldwide customers ...
(Date:8/31/2014)... In the wake of growing consumer concerns ... to require mandatory labeling of GMOs on food and ... that affect their own health and the health of ... measures to eliminate GMOs from dietary supplements, NutriGold has ... initiative with the objective of advancing the non-GMO ...
(Date:8/31/2014)... 01, 2014 Top10BestSEOHosting.com, a reliable review ... and announces that FatCow, Arvixe and Hostgator are the ... plenty of ASP.NET hosting companies in the world, but ... complicated to run a reliable ASP.NET server than running ... skills. I firmly believe that FatCow, Arvixe and Hostgator ...
(Date:8/31/2014)... Ticket Down is a dependable source ... at the Sun Life Stadium in early September. Diehard soccer ... game on September 5th between Colombia and Brazil will likely set ... year between Brazil and Honduras at Sun Life Stadium brought in ... and has also been the home of the Florida Marlins of ...
Breaking Medicine News(10 mins):Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:Delta Updates Its Wheel Loader Assortment With A Lot Of Cheap Used Cat 966 Loaders 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3Health News:Best ASP.NET Hosting Award for August 2014 Released By Top10BestSEOHosting.com 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for September 5th Match 2Health News:Brazil vs. Colombia Tickets in Miami: Ticket Down Slashes Colombia vs. Brazil Tickets at Sun Life Stadium in Miami for September 5th Match 3
... Whole genome sequencing spelling out a person,s entire ... being a medical option for direct patient care. Physicians ... Genomics Research Institute (TGen) successfully completed sequencing both a single ... of more than 6 billion DNA chemical bases. While ...
... patients were more likely to be readmitted to the hospital ... failure, or pneumonia, according to a new study from Harvard ... higher readmission rates were due to disparities related to both ... "Disparities in health and health care are well-documented in this ...
... Reporter , TUESDAY, Feb. 15 (HealthDay News) -- After ... older black people are more likely to be readmitted ... study finds. Overall, older blacks have 13 percent ... research suggests, while patients treated at hospitals that primarily ...
... two-thirds of California,s 7 million uninsured residents will become eligible ... in 2014, according to a new policy brief from the ... study draws on the latest data from the California Health ... The policy brief, "Two-thirds of California,s 7 Million Uninsured ...
... , TUESDAY, Feb. 15 (HealthDay News) -- Motorcycle helmets reduce ... a widely held belief that the weight of motorcycle helmets ... a popular myth that wearing a helmet while riding a ... Dr. Adil H. Haider, an assistant professor of surgery at ...
... HealthDay Reporter , TUESDAY, Feb. 15 (HealthDay News) ... women and men, with a few small but important differences, ... Each year, 55,000 more U.S. women than men suffer a ... One strong risk factor for stroke is atrial ...
Cached Medicine News:Health News:Whole genome sequencing used to help inform cancer therapy 2Health News:Whole genome sequencing used to help inform cancer therapy 3Health News:Study finds blacks more likely to be readmitted to hospitals after discharge 2Health News:Blacks Readmitted to Hospital More Than Whites: Study 2Health News:Blacks Readmitted to Hospital More Than Whites: Study 3Health News:4.7 million Californians to gain coverage under health reform, new study estimates 2Health News:4.7 million Californians to gain coverage under health reform, new study estimates 3Health News:Motorcycle Helmets Help Protect Against Spine Injury: Study 2Health News:Experts Issue New Heart Disease Guidelines for Women 2Health News:Experts Issue New Heart Disease Guidelines for Women 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: